Edward Mezones-Holguín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edward Mezones-Holguín has a total of 344 co-authors. Here are the top co-authors by number of shared publications:
Peter Chedraui
Escuela de Posgrado en Salud, Universidad Espíritu Santo, Samborondón, Ecuador
12 shared publicationsAlvaro Monterrosa
Collaborative Group for Research of the Climacteric in Latin America (REDLINC)
11 shared publicationsAscanio Bencosme
Collaborative Group for Research of the Climacteric in Latin America (REDLINC)
11 shared publications- Báltica Cabieses
Universidad del Desarrollo
11 shared publications Daniel Flores
Collaborative Group for Research of the Climacteric in Latin America (REDLINC)
11 shared publicationsJuan E. Blümel
Faculty of Medicine, Universidad de Chile, Santiago de Chile, Chile
11 shared publications
Latest Publications
- 3 April 2026
- Published by Taylor & Francis in International Journal of Injury Control and Safety Promotion
- Vol. 33 (2) , 322-334
Reducing homicides and homicide education inequalities: deterrence and negotiation in Colombian security policies over 1999–2017
This study examines long-term trends (1999-2017) in homicide rates and socioeconomic disparities in Colombia, a country marked by decades of armed conflict, organized crime and structural inequality. We used national mortality data, applying age-standardized rates, the Relative Index of Inequality (RII) and Joinpoint regression to assess trends and educational disparities. Homicide rates declined substantially for men and women, demonstrating the effectiveness of renewed state capacity and security interventions. However, this macroscopic success was highly uneven: gaps in lethal violence by educational attainment widened for most of the study period, underscoring a critical policy dilemma. These findings show that reductions in homicide did not translate into proportional declines in socioeconomic disparities. Sustainable and equitable violence reduction requires a dual-track strategy combining deterrence and structural equity. Crucially, successful transitions to peace demand the strategic weakening of illegal armed structures be prioritized before, or concurrently with, formal peace negotiations.
- 3 April 2026
- Published by Taylor & Francis in International Journal of Injury Control and Safety Promotion
- Vol. 33 (2) , 322-334
Reducing homicides and homicide education inequalities: deterrence and negotiation in Colombian security policies over 1999–2017
This study examines long-term trends (1999-2017) in homicide rates and socioeconomic disparities in Colombia, a country marked by decades of armed conflict, organized crime and structural inequality. We used national mortality data, applying age-standardized rates, the Relative Index of Inequality (RII) and Joinpoint regression to assess trends and educational disparities. Homicide rates declined substantially for men and women, demonstrating the effectiveness of renewed state capacity and security interventions. However, this macroscopic success was highly uneven: gaps in lethal violence by educational attainment widened for most of the study period, underscoring a critical policy dilemma. These findings show that reductions in homicide did not translate into proportional declines in socioeconomic disparities. Sustainable and equitable violence reduction requires a dual-track strategy combining deterrence and structural equity. Crucially, successful transitions to peace demand the strategic weakening of illegal armed structures be prioritized before, or concurrently with, formal peace negotiations.
- 1 May 2025
- Published by Springer Nature
- p. 135-157
Utilization of Health Services
- Open Access
- 26 November 2024
- Vol. 41 (4) , 422-430
The null hypothesis significance test and the dichotomization of the p-value: Errare Humanum Est
Decision-making in healthcare is complex and needs to be based on the best scientific evidence. In this process, information derived from statistical analysis of data is crucial, which can be developed from either frequentist or Bayesian perspectives. When it comes to the frequentist field, the null hypothesis significance test (NHST) and its p-value is one of the most widely used techniques in different disciplines. However, NHST has been subjected to questioning from different academic points of view, which has led to it being considered as one of the causes of the so-called replicability crisis in science. In this review article, we provide a brief historical account of its development, summarize the underlying methods, describe some controversies and limitations, address misuse and misinterpretation, and finally give some scopes and reflections in the context of biomedical research.
- 26 November 2024
- Vol. 41 (4) , 422-430
Open AccessThe null hypothesis significance test and the dichotomization of the p-value: Errare Humanum Est
Decision-making in healthcare is complex and needs to be based on the best scientific evidence. In this process, information derived from statistical analysis of data is crucial, which can be developed from either frequentist or Bayesian perspectives. When it comes to the frequentist field, the null hypothesis significance test (NHST) and its p-value is one of the most widely used techniques in different disciplines. However, NHST has been subjected to questioning from different academic points of view, which has led to it being considered as one of the causes of the so-called replicability crisis in science. In this review article, we provide a brief historical account of its development, summarize the underlying methods, describe some controversies and limitations, address misuse and misinterpretation, and finally give some scopes and reflections in the context of biomedical research.
- Open Access
- 26 November 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 422-30
La prueba de significancia de la hipótesis nula y la dicotomización del valor p: Errare Humanum Est
Decision-making in healthcare is complex and needs to be based on the best scientific evidence. In this process, information derived from statistical analysis of data is crucial, which can be developed from either frequentist or Bayesian perspectives. When it comes to the frequentist field, the null hypothesis significance test (NHST) and its p-value is one of the most widely used techniques in different disciplines. However, NHST has been subjected to questioning from different academic points of view, which has led to it being considered as one of the causes of the so-called replicability crisis in science. In this review article, we provide a brief historical account of its development, summarize the underlying methods, describe some controversies and limitations, address misuse and misinterpretation, and finally give some scopes and reflections in the context of biomedical research.
- 26 November 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 422-30
Open AccessLa prueba de significancia de la hipótesis nula y la dicotomización del valor p: Errare Humanum Est
Decision-making in healthcare is complex and needs to be based on the best scientific evidence. In this process, information derived from statistical analysis of data is crucial, which can be developed from either frequentist or Bayesian perspectives. When it comes to the frequentist field, the null hypothesis significance test (NHST) and its p-value is one of the most widely used techniques in different disciplines. However, NHST has been subjected to questioning from different academic points of view, which has led to it being considered as one of the causes of the so-called replicability crisis in science. In this review article, we provide a brief historical account of its development, summarize the underlying methods, describe some controversies and limitations, address misuse and misinterpretation, and finally give some scopes and reflections in the context of biomedical research.
- Open Access
- 25 March 2024
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 40 (1) , 2328619
Efficacy and safety of visnadine in the treatment of symptoms of sexual dysfunction in heterosexual women: a systematic review of randomized clinical trials
To synthesize the primary evidence on the efficacy and safety of visnadine on symptoms of sexual dysfunction (SD) in heterosexual women. We conducted a systematic review of randomized clinical trials (RCTs) with a primary search without language restriction in PubMed/Medline, Scopus, Embase, Web of Science, Cochrane Library, and international clinical trial registries. Trials reporting the use of visnadine by any route in women with SD were eligible. We performed screening, data extraction, and risk of bias assessment in a double-blind approach. The primary outcomes were the Female Sexual Function Index (FSFI) and its domains. Secondary outcomes were safety, arousal, lubrication, pleasure, orgasm, negative sensations, duration, and overall satisfaction. Initially, 242 records were retrieved. We selected nine papers for full-text reading and finally included two RCTs: one with a parallel design and one with a crossover design with a total of 96 patients. One study compared visnadine aerosol with a placebo, while the other compared different frequencies of visnadine aerosol use. Visnadine use showed a statistically significant improvement (p < 0.05) in overall FSFI scores, regardless of the frequency of use. A meta-analysis was not possible due to the high clinical and methodological heterogeneity between available studies. RCTs regarding the use of visnadine for the Female SD are scarce and methodologically limited. This preliminary evidence shows visnadine as a potentially effective and safe option to alleviate some of the clinical symptoms of SD in heterosexual women. However, future better-designed randomized studies with larger sample numbers are required.
- 25 March 2024
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 40 (1) , 2328619
Open AccessEfficacy and safety of visnadine in the treatment of symptoms of sexual dysfunction in heterosexual women: a systematic review of randomized clinical trials
To synthesize the primary evidence on the efficacy and safety of visnadine on symptoms of sexual dysfunction (SD) in heterosexual women. We conducted a systematic review of randomized clinical trials (RCTs) with a primary search without language restriction in PubMed/Medline, Scopus, Embase, Web of Science, Cochrane Library, and international clinical trial registries. Trials reporting the use of visnadine by any route in women with SD were eligible. We performed screening, data extraction, and risk of bias assessment in a double-blind approach. The primary outcomes were the Female Sexual Function Index (FSFI) and its domains. Secondary outcomes were safety, arousal, lubrication, pleasure, orgasm, negative sensations, duration, and overall satisfaction. Initially, 242 records were retrieved. We selected nine papers for full-text reading and finally included two RCTs: one with a parallel design and one with a crossover design with a total of 96 patients. One study compared visnadine aerosol with a placebo, while the other compared different frequencies of visnadine aerosol use. Visnadine use showed a statistically significant improvement (p < 0.05) in overall FSFI scores, regardless of the frequency of use. A meta-analysis was not possible due to the high clinical and methodological heterogeneity between available studies. RCTs regarding the use of visnadine for the Female SD are scarce and methodologically limited. This preliminary evidence shows visnadine as a potentially effective and safe option to alleviate some of the clinical symptoms of SD in heterosexual women. However, future better-designed randomized studies with larger sample numbers are required.
- Open Access
- 26 January 2024
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (2, mar-abr) , 191-197
Desafíos para el abordaje de la salud de los migrantes en Chile durante la pandemia por Covid-19: una revisión de alcance
Objetivo. Indagar sobre los principales desafíos reportados en el marco de la emergencia sanitaria de SARS-CoV-2 según la evidencia científica disponible a la fecha en esta materia en Chile. Material y métodos. Revisión de alcance con base en tres búsquedas en Web of Science, PubMed y Google Scholar de publicaciones en inglés y español publicadas entre 2020 y 2023. Resultados. Se identificaron tres áreas clave: desafíos de acceso y uso efectivo del sistema de salud, desafíos más allá del sistema de salud, incluyendo aquellas relaciones con determinantes sociales de la salud, autocuidado e información y, finalmente, desafíos de integración de los enfoques de interculturalidad, género y cooperación internacional. Conclusiones. Se evidencian oportunidades de mejorar el abordaje de la salud de personas migrantes internacionales en Chile a raíz de la pandemia por Covid-19, de cara a futuras crisis sanitarias y para reducir brechas e inequidades que impactan la salud poblacional.
- 26 January 2024
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (2, mar-abr) , 191-197
Open AccessDesafíos para el abordaje de la salud de los migrantes en Chile durante la pandemia por Covid-19: una revisión de alcance
Objetivo. Indagar sobre los principales desafíos reportados en el marco de la emergencia sanitaria de SARS-CoV-2 según la evidencia científica disponible a la fecha en esta materia en Chile. Material y métodos. Revisión de alcance con base en tres búsquedas en Web of Science, PubMed y Google Scholar de publicaciones en inglés y español publicadas entre 2020 y 2023. Resultados. Se identificaron tres áreas clave: desafíos de acceso y uso efectivo del sistema de salud, desafíos más allá del sistema de salud, incluyendo aquellas relaciones con determinantes sociales de la salud, autocuidado e información y, finalmente, desafíos de integración de los enfoques de interculturalidad, género y cooperación internacional. Conclusiones. Se evidencian oportunidades de mejorar el abordaje de la salud de personas migrantes internacionales en Chile a raíz de la pandemia por Covid-19, de cara a futuras crisis sanitarias y para reducir brechas e inequidades que impactan la salud poblacional.
- 24 October 2023
- Published by Wolters Kluwer Health in Menopause
- Vol. 30 (12) , 1230-1240
Short-term effects and safety of a natural oral supplement containing glucosinolates, phytosterols, and citrus flavonoids compared with hormone treatment for the management of postmenopausal symptomatic women: a pilot single-center randomized phase 2 clinical trial
Objective: This study aimed to evaluate the short-term efficacy and safety of an oral herbal supplement containing glucosinolates, phytosterols, and citrus flavonoids for menopausal symptoms in comparison with estrogen plus progestogen therapy (EPT) among postmenopausal women. Methods: This was a pilot single-blinded, three-armed phase II randomized clinical trial, controlled with EPT. Sixty participants were randomly assigned to receive treatment for 3 months: (1) an oral herbal supplement of 1,500 mg/d (G1, n = 20), (2) an oral herbal supplement of 3,000 mg/d (G2, n = 20), or (3) conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate of 5 mg/d (EPT group, n = 20). The primary endpoint was the intensity of menopausal symptoms as measured using the Menopause-Specific Quality of Life Questionnaire (global and domain scores). The Menopause-Specific Quality of Life Questionnaire uses a 7-point scale to rate the symptom intensity, with higher scores indicating severity. The secondary endpoints were hormonal, lipid, and safety profiles. Results: Fifty-four participants (n = 54) completed the study. The mean, model-estimated, and global menopausal symptom scores at 3 months were 85.8 in the EPT group, 61.3 in G1, and 62.5 in G2. Participants treated with the herbal compound had lower global (13.7 [6.9-20.4], P < 0.001) and physical symptom scores (6.6 [1.6-11.5], P = 0.002) on the second month and lower psychosocial symptom scores (3.8 [1.3 to 6.3], P < 0.001) on the third month of follow-up, compared with EPT. Conversely, participants receiving EPT showed better outcomes on vasomotor symptoms since the first month of treatment (−6.1 [−8.3 to −4.0], P < 0.001). The EPT group exhibited higher values of estradiol and lower follicle-stimulating hormone and luteinizing hormone since the first month of follow-up. Also, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were significantly higher in this group than in G2. Conclusions: In this small single-blind exploratory trial, the oral herbal supplement was more efficacious in reducing global, physical, and psychosocial menopausal symptoms in the short term than EPT. However, further studies are needed to adequately assess the efficacy and safety of this herbal supplement in the treatment of menopausal symptoms.
- 24 October 2023
- Published by Wolters Kluwer Health in Menopause
- Vol. 30 (12) , 1230-1240
Short-term effects and safety of a natural oral supplement containing glucosinolates, phytosterols, and citrus flavonoids compared with hormone treatment for the management of postmenopausal symptomatic women: a pilot single-center randomized phase 2 clinical trial
Objective: This study aimed to evaluate the short-term efficacy and safety of an oral herbal supplement containing glucosinolates, phytosterols, and citrus flavonoids for menopausal symptoms in comparison with estrogen plus progestogen therapy (EPT) among postmenopausal women. Methods: This was a pilot single-blinded, three-armed phase II randomized clinical trial, controlled with EPT. Sixty participants were randomly assigned to receive treatment for 3 months: (1) an oral herbal supplement of 1,500 mg/d (G1, n = 20), (2) an oral herbal supplement of 3,000 mg/d (G2, n = 20), or (3) conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate of 5 mg/d (EPT group, n = 20). The primary endpoint was the intensity of menopausal symptoms as measured using the Menopause-Specific Quality of Life Questionnaire (global and domain scores). The Menopause-Specific Quality of Life Questionnaire uses a 7-point scale to rate the symptom intensity, with higher scores indicating severity. The secondary endpoints were hormonal, lipid, and safety profiles. Results: Fifty-four participants (n = 54) completed the study. The mean, model-estimated, and global menopausal symptom scores at 3 months were 85.8 in the EPT group, 61.3 in G1, and 62.5 in G2. Participants treated with the herbal compound had lower global (13.7 [6.9-20.4], P < 0.001) and physical symptom scores (6.6 [1.6-11.5], P = 0.002) on the second month and lower psychosocial symptom scores (3.8 [1.3 to 6.3], P < 0.001) on the third month of follow-up, compared with EPT. Conversely, participants receiving EPT showed better outcomes on vasomotor symptoms since the first month of treatment (−6.1 [−8.3 to −4.0], P < 0.001). The EPT group exhibited higher values of estradiol and lower follicle-stimulating hormone and luteinizing hormone since the first month of follow-up. Also, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were significantly higher in this group than in G2. Conclusions: In this small single-blind exploratory trial, the oral herbal supplement was more efficacious in reducing global, physical, and psychosocial menopausal symptoms in the short term than EPT. However, further studies are needed to adequately assess the efficacy and safety of this herbal supplement in the treatment of menopausal symptoms.
- 6 July 2023
- Published by Wiley in Tropical Medicine & International Health
- Vol. 28 (8) , 641-652
Highly active antiretroviral therapy discontinuation time is associated with therapeutic failure among human immunodeficiency virus (HIV)‐infected immigrant adults: A cohort study from a Peruvian referral hospital during the Venezuelan exodus
Objective: To evaluate the association between Highly Active Antiretroviral Therapy (HAART) discontinuation time and therapeutic failure (TF) in Venezuelan immigrants with HIV that restart HAART.Methods: We carried out a retrospective cohort study in a large hospital in Peru. We included Venezuelan immigrants who restarted HAART and were followed over at least 6 months. The primary outcome was TF. Secondary outcomes were immunologic (IF), virologic (VF) and clinical (CF) failures. The exposure variable was HAART discontinuation, categorised as no discontinuation, less than 6 months, and 6 months or more. We applied generalised linear models Poisson family with robust standard errors to calculate crude (cRR) and adjusted (aRR) relative risks by statistical and epidemiological criteria.Results: We included 294 patients, 97.2% were males, and the median age was 32 years. Out of all the patients, 32.7% discontinued HAART for less than 6 months, 15.0% discontinued for more than 6 months and the remaining 52.3% did not discontinue. The cumulative incidence of TF was 27.9%, 24.5% in VF, 6.0% in IF and 6.0% in CF. Compared with non‐discontinued HAART patients, the discontinuation for less than 6 months (aRR = 1.98 [95% CI: 1.27–3.09]) and from 6 months to more (aRR = 3.17 [95% CI: 2.02–4.95]) increased the risk of TF. Likewise, treatment discontinuation of up to 6 months (aRR = 2.32 [95% CI: 1.40–3.84]) and from 6 months to more (aRR = 3.93 [95% CI: 2.39–6.45]) increased the risk of VF.Conclusions: HAART discontinuation increases the probability of TF and VF in Venezuelan immigrants.
- 6 July 2023
- Published by Wiley in Tropical Medicine & International Health
- Vol. 28 (8) , 641-652
Highly active antiretroviral therapy discontinuation time is associated with therapeutic failure among human immunodeficiency virus (HIV)‐infected immigrant adults: A cohort study from a Peruvian referral hospital during the Venezuelan exodus
Objective: To evaluate the association between Highly Active Antiretroviral Therapy (HAART) discontinuation time and therapeutic failure (TF) in Venezuelan immigrants with HIV that restart HAART.Methods: We carried out a retrospective cohort study in a large hospital in Peru. We included Venezuelan immigrants who restarted HAART and were followed over at least 6 months. The primary outcome was TF. Secondary outcomes were immunologic (IF), virologic (VF) and clinical (CF) failures. The exposure variable was HAART discontinuation, categorised as no discontinuation, less than 6 months, and 6 months or more. We applied generalised linear models Poisson family with robust standard errors to calculate crude (cRR) and adjusted (aRR) relative risks by statistical and epidemiological criteria.Results: We included 294 patients, 97.2% were males, and the median age was 32 years. Out of all the patients, 32.7% discontinued HAART for less than 6 months, 15.0% discontinued for more than 6 months and the remaining 52.3% did not discontinue. The cumulative incidence of TF was 27.9%, 24.5% in VF, 6.0% in IF and 6.0% in CF. Compared with non‐discontinued HAART patients, the discontinuation for less than 6 months (aRR = 1.98 [95% CI: 1.27–3.09]) and from 6 months to more (aRR = 3.17 [95% CI: 2.02–4.95]) increased the risk of TF. Likewise, treatment discontinuation of up to 6 months (aRR = 2.32 [95% CI: 1.40–3.84]) and from 6 months to more (aRR = 3.93 [95% CI: 2.39–6.45]) increased the risk of VF.Conclusions: HAART discontinuation increases the probability of TF and VF in Venezuelan immigrants.
- Open Access
- 20 June 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 40, 100538
Intersections between gender approaches, migration and health in Latin America and the Caribbean: a discussion based on a scoping review
- 20 June 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 40, 100538
Open AccessIntersections between gender approaches, migration and health in Latin America and the Caribbean: a discussion based on a scoping review
- Open Access
- 16 June 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 23, 100532
Vaccine-derived polio in Peru after 32 years of elimination: reflections on the routine childhood immunisation coverages
- 16 June 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 23, 100532
Open AccessVaccine-derived polio in Peru after 32 years of elimination: reflections on the routine childhood immunisation coverages